Spermatogenic Failure 18 (SPGF18) Cell Models for Research

Spermatogenic Failure 18 (SPGF18) is a rare genetic disorder characterized by male infertility due to defective spermatogenesis. The exact prevalence is unknown, but it is estimated to affect a small fraction of infertile men. The condition is inherited in an autosomal recessive manner. According to the World Health Organization (WHO), infertility affects approximately 15% of couples worldwide, with male factors contributing to about 50% of cases. SPGF18 is caused by mutations in the DMRT1 gene, which plays a critical role in testis development and spermatogenesis. The clinical impact is significant, as affected individuals experience azoospermia or severe oligospermia, leading to infertility. There is no cure, and assisted reproductive technologies may be the only option for some patients. Research into the molecular mechanisms of SPGF18 is essential for developing potential therapies and improving diagnostic accuracy.

SPGF18 serves as an excellent model for studying spermatogenesis and male infertility. The DMRT1 gene is a master regulator of testis differentiation and maintenance of spermatogonial stem cells. By studying SPGF18, researchers can gain insights into the molecular pathways governing germ cell development, meiosis, and sperm maturation. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas, provide expression data for DMRT1 in testicular tissues. However, there are still open questions regarding the precise downstream targets of DMRT1 and how its loss leads to spermatogenic failure. Gene-edited cell models, such as DMRT1 knockout cell lines, are invaluable tools to dissect these pathways and identify potential therapeutic targets.

SPGF18 is not a cancer, but a developmental disorder. However, DMRT1 is involved in testicular germ cell tumor (TGCT) susceptibility. DMRT1 acts as a tumor suppressor in the testis, and its loss can lead to both spermatogenic failure and increased risk of TGCT. The major pathways affected include:

• • DMRT1-mediated transcriptional regulation: DMRT1 regulates genes involved in spermatogonial stem cell maintenance, meiosis, and Sertoli cell function.
• • Retinoic acid (RA) signaling: DMRT1 modulates RA signaling, which is crucial for the transition from mitotic to meiotic germ cells.
• • p53 pathway: DMRT1 interacts with p53 to regulate apoptosis and DNA repair in germ cells.
• • Wnt signaling: DMRT1 influences Wnt signaling, which is important for cell proliferation and differentiation in the testis.

Data from ClinVar and COSMIC databases.

DMRT1 loss disrupts several signaling networks:

• • Retinoic acid (RA) signaling: DMRT1 represses RA-responsive genes in spermatogonia; its loss leads to premature meiotic entry and depletion of the stem cell pool.
• • p53 pathway: DMRT1 cooperates with p53 to induce apoptosis in damaged germ cells; loss impairs DNA damage response.
• • Wnt/β-catenin signaling: DMRT1 interacts with β-catenin to regulate Sertoli cell function; dysregulation affects the blood-testis barrier.
• • Notch signaling: DMRT1 influences Notch pathway components, affecting cell fate decisions in the testis.

Organoids derived from testicular tissue can recapitulate spermatogenesis in vitro, providing a more physiologically relevant model. However, they are technically challenging and have limited throughput.

• • DMRT1 knockout mice: Global or conditional knockout leads to spermatogenic failure and Sertoli cell dysfunction, mimicking SPGF18.
• • DMRT1 conditional knockout in Sertoli cells: Allows study of cell-specific effects.
• • DMRT1 overexpression models: Used to study its tumor suppressor role in TGCT.
• • Patient-derived xenografts (PDX): Not commonly used for SPGF18 due to the non-cancerous nature, but testicular tumor PDX models exist for TGCT.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise DMRT1 mutations. For example, a DMRT1 knockout in a human spermatogonial stem cell line (e.g., GC-1 spg) can be generated to study the loss-of-function phenotype. Alternatively, knock-in of a specific pathogenic mutation (e.g., c.123C>A, p.Tyr41*) can be introduced to model the disease. These gene-edited cell models are sequence-verified and can be used for functional studies, drug screening, and target validation. Commercially available, these models accelerate research by providing consistent and reproducible tools.

Gene-edited cell lines with DMRT1 knockout or knock-in mutations allow researchers to study the function of DMRT1 in spermatogenesis. For example, transcriptomic analysis of DMRT1 knockout cells can identify downstream target genes and pathways. Additionally, complementation studies with wild-type DMRT1 can confirm the specificity of the phenotype.

Isogenic pairs (wild-type vs. DMRT1 knockout) can be used in high-throughput screens to identify compounds that rescue the spermatogenic defect. For instance, small molecules that activate RA signaling or bypass DMRT1 loss could be potential therapeutic candidates. Resistance models can be developed to study how germ cells adapt to DMRT1 loss.

CRISPR synthetic lethality screens using DMRT1 knockout cells can identify genes that are essential for survival in the absence of DMRT1. These genes could serve as potential drug targets for TGCT, where DMRT1 is often lost. Additionally, secretome analysis of DMRT1 knockout cells may reveal biomarkers for non-invasive diagnosis of spermatogenic failure.